Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.90 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14423989 | 0.98 | EPHX1 (0.87) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7440101 | 0.95 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL26677285 | 0.95 | EPHX1 (0.87) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196095 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL652844 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7561514 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL4997375 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL1059134 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196099 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196092 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-7732416-B2 | For protecting plants against parasitic feeding pests; also against the infestation of pets, especially cats and dogs, by fleas, ticks and nematodes; pesticides for crop protection | MERIAL LIMITED (US) | 2010-06-08 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| US-7538149-B2 | Ink composition, inkjet recording method, printed material, process for producing lithographic printing plate, and lithographic printing plate | FUJIFILM CORPORATION (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0346339-B1 | BARBITURIC ACID COMPOUNDS, PHOTORESISTS THEREFROM AND METHOD FOR PREPARATION | HOECHST CELANESE CORPORATION (US) | 1992-09-09 | — | — | EP | disclosed |
| US-4902784-A | 1,3 Disubstituted-5-diazobarbituric acids | HOECHST CELANESE CORPORATION (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0346339-A1 | BARBITURIC ACID COMPOUNDS, PHOTORESISTS THEREFROM AND METHOD FOR PREPARATION. | HOECHST CELANESE CORP (US) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989005800-A1 | NOVEL BARBITURIC ACID COMPOUNDS, PHOTORESISTS THEREFROM AND METHOD FOR PREPARATION | HOECHST CELANESE CORPORATION (US) | 1989-06-29 | — | — | WO | disclosed |
| US-4735885-A | Deep UV photoresist composition with 1,3-disubstituted-5-diazobarbituric acids | ALLIED CORPORATION (US) | 1988-04-05 | — | — | US | disclosed |
| US-3936484-A | Production of isocyanates from substituted ureas | ATLANTIC RICHFIELD COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | EPHX1 1109/4885EPHX2 558/4885KDM4E 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.